Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
BMJ Open. 2013 Sep 27;3(9):e003066. doi: 10.1136/bmjopen-2013-003066.
To examine cytomegalovirus (CMV) seroprevalence and associated risk factors for CMV seropositivity in pregnant Norwegian women.
Cross-sectional study.
The Norwegian Mother and Child Cohort Study (MoBa) in addition to two random samples of pregnant women from Sør-Trøndelag County in Norway.
Study group 1 were 1000 pregnant women, randomly selected among 46 127 pregnancies in the MoBa (1999-2006) at 17/18 week of gestation. Non-ethnic Norwegian women were excluded. Study groups 2 (n=1013 from 1995) and 3 (n=979 from 2009) were pregnant women at 12 weeks of gestation from Sør-Trøndelag County.
CMV seropositivity in blood samples from pregnant Norwegian women.
CMV-IgG antibodies were detected in 59.9% and CMV-IgM antibodies in 1.3% of pregnant Norwegian women in study group 1. Women from North Norway demonstrated a higher CMV-IgG seroprevalence (72.1%) than women from South Norway (58.5%) (OR 1.83, 95% CI 1.17 to 2.88). The CMV-IgG seroprevalence was higher among women with low education (70.5%) compared to women with higher education (OR 2.20, 95% CI 1.24 to 3.90). Between 1995 and 2009 the CMV-IgG seroprevalence increased from 63.1% to 71.4% in pregnant women from Sør-Trøndelag County (study groups 2 and 3; p<0.001). The highest CMV-IgG seroprevalence (79.0%) was observed among the youngest pregnant women (<25 years) from Sør-Trøndelag County in 2009 (study group 3).
The CMV-IgG seroprevalence of pregnant Norwegian women varies with geographic location and educational level. Additionally, the CMV-IgG seroprevalence appears to have increased over the last years, particularly among young pregnant women.
检测挪威孕妇巨细胞病毒(CMV)血清阳性率及其与 CMV 血清阳性的相关危险因素。
横断面研究。
挪威莫巴(1999-2006 年)中 46127 例妊娠的 1000 例孕妇为研究组 1,这是一项随机抽样研究。排除非挪威裔的孕妇。研究组 2(1995 年,1013 例)和 3(2009 年,979 例)是来自特隆赫姆郡的 12 周妊娠孕妇。
1000 例孕妇是在妊娠 17/18 周时从 46127 例妊娠中随机抽取的莫巴研究(1999-2006 年)中的 1000 例孕妇(1999-2006 年)。排除非挪威族裔的孕妇。研究组 2(1995 年,1013 例)和 3(2009 年,979 例)是来自特隆赫姆郡的 12 周妊娠孕妇。
挪威孕妇血液样本中的 CMV 血清阳性率。
在研究组 1 中,59.9%的挪威孕妇检测到 CMV-IgG 抗体,1.3%的孕妇检测到 CMV-IgM 抗体。来自挪威北部的孕妇 CMV-IgG 血清阳性率(72.1%)高于来自挪威南部的孕妇(58.5%)(OR 1.83,95%CI 1.17-2.88)。文化程度较低的孕妇(70.5%)CMV-IgG 血清阳性率高于文化程度较高的孕妇(OR 2.20,95%CI 1.24-3.90)。1995 年至 2009 年期间,特隆赫姆郡孕妇(研究组 2 和 3)CMV-IgG 血清阳性率从 63.1%上升至 71.4%(p<0.001)。2009 年,来自特隆赫姆郡最年轻的孕妇(<25 岁)CMV-IgG 血清阳性率最高(79.0%)(研究组 3)。
挪威孕妇的 CMV-IgG 血清阳性率随地理位置和教育水平而变化。此外,CMV-IgG 血清阳性率似乎在过去几年有所上升,尤其是在年轻孕妇中。